Oluwadunsin Iyanuoluwa Adebayo

Oluwadunsin Iyanuoluwa Adebayo

Auto-generated profile, based on publicly available information

Oluwadunsin Iyanuoluwa Adebayo


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Informatics in Medicine Unlocked
Verified
Journal Article
Open access
Elijah Kolawole OladipoElijah Kolawole Oladipo
Elijah Kolawole Oladipo
AAAyodeji Folorunsho Ajayi
Ayodeji Folorunsho Ajayi
OAOlumuyiwa Elijah Ariyo
Olumuyiwa Elijah Ariyo
Olugbenga Samson OnileOlugbenga Samson Onile
Olugbenga Samson Onile
EJEsther Moradeyo Jimah
Esther Moradeyo Jimah
JOJulius Kola Oloke
Julius Kola Oloke
Stimulation and generation of T and B cell-mediated long-term immune response are essential for the curbing of a deadly virus such as SAR-CoV-2 (Severe Acute Respiratory Corona Virus 2). Immunoinformatics approach in vaccine design takes advantage of antigenic and non-allergenic epitopes present on the spike glycoprotein of SARS-CoV-2 to elicit immune responses. T cells and B cells epitopes were predicted, and the selected residues were subjected to allergenicity, antigenicity and toxicity screening which were linked by appropriate linkers to form a multi-epitope subunit vaccine. The physiochemical properties of the vaccine construct were analyzed, and the molecular weight, molecular formula, theoretical isoelectric point value, half-life, solubility score, instability index, aliphatic index and GRAVY were predicted. The vaccine structure was constructed, refined, validated, and disulfide engineered to get the best model. Molecular binding simulation and molecular dynamics simulation were carried out to predict the stability and binding affinity of the vaccine construct with TLRs. Codon acclimatization and in silico cloning were performed to confirm the vaccine expression and potency. Results obtained indicated that this novel vaccine candidate is non-toxic, capable of initiating the immunogenic response and will not induce an allergic reaction. The highest binding energy was observed in TLR4 (Toll-like Receptor 4) (−1398.1), and the least is TLR 2 (−1479.6). The steady rise in Th (T-helper) cell population with memory development was noticed, and IFN-g (Interferon gamma) was provoked after simulation. At this point, the vaccine candidate awaits animal trial to validate its efficacy and safety for use in the prevention of the novel COVID-19 (Coronavirus Disease 2019) infections.

1 September 2021 in Endocrine and Metabolic Science
Verified
Journal Article
Open access
AAAyodeji Folorunsho Ajayi
Ayodeji Folorunsho Ajayi
OLOlubodun Michael Lateef
Olubodun Michael Lateef
OAOluwadunsi Iyanuoluwa Adebayo
Oluwadunsi Iyanuoluwa Adebayo
EAEmmanuel Tayo Adebayo
Emmanuel Tayo Adebayo